Recently, immunotherapy has changed the paradigm of MM management, as the transmembrane glycoprotein cluster of differentiation 38 (CD38), which is highly expressed in MM cells, is a target for new therapeutic antibodies such as isatuximab and daratumumab.6 The gene discussed is CD38; the disease is Miyoshi myopathy.